Note: This story was updated March 17, 2025, to correct the attribution of quotes to Sonya Dumanis, PhD, deputy director of Aligning Science Across Parkinson’s. The Aligning Science Across Parkinson’s (ASAP) initiative is investing $6 million in research grants to support the development of new tools — including cell…
A small Phase 1 clinical trial testing a treatment approach that uses stem cells derived from a patient’s blood cells to replace the dopamine-producing neurons progressively lost in Parkinson’s disease is looking for three more patients. The first-of-its-kind Phase 1 study (NCT06422208), being conducted at Harvard Medical School’s…
The number of people with Parkinson’s disease is likely to more than double in the next years, topping 25 million worldwide by 2050, mainly because the world’s population is living longer, a study found. The largest increases are projected to be in East Asia, where nearly 11 million people…
A daily dose of CPL’36, an oral small molecule in the pipeline of Celon Pharma, may ease symptoms for patients who experience levodopa-induced dyskinesia, or uncontrolled movements as a side effect of the mainstay Parkinson’s disease treatment, within one week. That’s according to data from a Phase 2 clinical…
Inserting a piece of nerve tissue from a patient’s ankle into the brain during deep brain stimulation (DBS) surgery appears a safe and feasible way to support damaged dopaminergic neurons in Parkinson’s disease, with the goal of slowing symptom progression. That’s according to results from a Phase 1…
Men with Parkinson’s disease mount stronger and more frequent immune responses than do women against PINK1, a protein that protects nerve cells from death, a new U.S. study found. These findings offer new clues for how the immune system shapes the course of disease in men and women, the…
Thirteen blood biomarkers, including three never previously linked to Parkinson’s disease, may help in diagnosing people sooner and scientists in better understanding the condition, according to a study based on data from nearly 400,000 people. “We identified several blood biomarkers that may be associated with the risk of developing…
A compound formed by nerve cells as they break down cholesterol appears to be involved in the formation of toxic alpha-synuclein protein clumps in the brain — clumps, or aggregates, that are tied to Parkinson’s disease — making this byproduct a potential therapeutic target, a new study in patients…
Male and female mice show different responses to toxic alpha-synuclein clumps, a hallmark of Parkinson’s disease, with males experiencing faster and more aggressive neurodegeneration and females showing earlier brain damage before motor symptoms appear, a study has found. Understanding these sex differences could help develop better, more personalized…
A global team of researchers has identified the molecular switch in a protein complex that regulates how cellular waste disposal mechanisms clean up and recycle unwanted materials — like the toxic alpha-synuclein protein clumps, or aggregates, that drive the death of nerve cells in Parkinson’s disease, according to a…
Get regular updates to your inbox.
